Adverum Biotechnologies, Inc. (NASDAQ: ADVM) Starts Presentation at 29th Annual ROTH Conference
Adverum (NASDAQ: ADVM) is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration, alpha-1 antitrypsin deficiency, and hereditary angioedema. Leveraging a next-generation adeno-associated virus-based directed evolution platform, the company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy…







